Chardan Capital Has Positive Outlook of LXEO FY2025 Earnings

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Equities researchers at Chardan Capital boosted their FY2025 EPS estimates for shares of Lexeo Therapeutics in a report released on Tuesday, April 8th. Chardan Capital analyst G. Livshits now forecasts that the company will post earnings per share of ($3.06) for the year, up from their previous estimate of ($3.10). Chardan Capital has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.09.

Several other research firms have also commented on LXEO. Leerink Partners lowered their price objective on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research note on Monday, March 24th. Royal Bank of Canada decreased their price target on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a research report on Tuesday, March 25th. Finally, HC Wainwright restated a “buy” rating and issued a $23.00 price target on shares of Lexeo Therapeutics in a research note on Tuesday. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $22.20.

Lexeo Therapeutics Stock Performance

Shares of Lexeo Therapeutics stock opened at $1.98 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. The stock has a market capitalization of $65.73 million, a price-to-earnings ratio of -0.63 and a beta of 1.52. The business has a 50-day moving average of $3.33 and a 200 day moving average of $5.97. Lexeo Therapeutics has a 12 month low of $1.45 and a 12 month high of $19.50.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Allostery Investments LP acquired a new stake in shares of Lexeo Therapeutics in the 4th quarter valued at $33,000. China Universal Asset Management Co. Ltd. purchased a new stake in Lexeo Therapeutics during the 4th quarter worth about $46,000. BNP Paribas Financial Markets boosted its position in shares of Lexeo Therapeutics by 184.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock worth $50,000 after acquiring an additional 3,591 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new position in shares of Lexeo Therapeutics in the 4th quarter valued at about $69,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Lexeo Therapeutics during the 4th quarter worth about $72,000. Hedge funds and other institutional investors own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.